These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32616337)

  • 1. Decreased levels of interleukin 27 in the serum of vitiligo patients.
    Hosseini SM; Gholijani N; Chenari N; Kalantar K
    An Bras Dermatol; 2020; 95(5):570-574. PubMed ID: 32616337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of TNF-α, IL-6, IL-17, IL-37 cytokines in patients with active vitiligo.
    Karagün E; Baysak S
    Aging Male; 2020 Dec; 23(5):1487-1492. PubMed ID: 33191834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulated human melanocytes express and release interleukin-8, which is inhibited by luteolin: relevance to early vitiligo.
    Miniati A; Weng Z; Zhang B; Therianou A; Vasiadi M; Nicolaidou E; Stratigos AJ; Antoniou C; Theoharides TC
    Clin Exp Dermatol; 2014 Jan; 39(1):54-7. PubMed ID: 23782102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T helper and regulatory T cell cytokine profile in active, stable and narrow band ultraviolet B treated generalized vitiligo.
    Tembhre MK; Sharma VK; Sharma A; Chattopadhyay P; Gupta S
    Clin Chim Acta; 2013 Sep; 424():27-32. PubMed ID: 23680073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine profile (IL-2, IL-6, IL-17, IL-22, and TNF-α) in vitiligo-New insight into pathogenesis of disease.
    Sushama S; Dixit N; Gautam RK; Arora P; Khurana A; Anubhuti A
    J Cosmet Dermatol; 2019 Feb; 18(1):337-341. PubMed ID: 29504235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of tumour necrosis factor-α -308A and interleukin-10 -1082G gene polymorphisms and increased serum levels of related cytokines: susceptibility to vitiligo.
    Aydıngöz IE; Kanmaz-Özer M; Gedikbaşi A; Vural P; Doğru-Abbasoğlu S; Uysal M
    Clin Exp Dermatol; 2015 Jan; 40(1):71-7. PubMed ID: 25283497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients.
    Singh S; Singh U; Pandey SS
    Indian J Dermatol; 2012 Jan; 57(1):12-4. PubMed ID: 22470201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines.
    Grimes PE; Morris R; Avaniss-Aghajani E; Soriano T; Meraz M; Metzger A
    J Am Acad Dermatol; 2004 Jul; 51(1):52-61. PubMed ID: 15243524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predominant role of innate pro-inflammatory cytokines in vitiligo disease.
    Gholijani N; Yazdani MR; Dastgheib L
    Arch Dermatol Res; 2020 Mar; 312(2):123-131. PubMed ID: 31620869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 1α and interleukin 18 in patients with vitiligo - Results of a case-control study.
    Nieradko-Iwanicka B; Przybylska D; Borzęcki A
    Biomed Pharmacother; 2023 Apr; 160():114364. PubMed ID: 36739764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions.
    Moretti S; Spallanzani A; Amato L; Hautmann G; Gallerani I; Fabiani M; Fabbri P
    Pigment Cell Res; 2002 Apr; 15(2):87-92. PubMed ID: 11936274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitexin protects melanocytes from oxidative stress via activating MAPK-Nrf2/ARE pathway.
    Li XS; Tang XY; Su W; Li X
    Immunopharmacol Immunotoxicol; 2020 Dec; 42(6):594-603. PubMed ID: 33045867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum levels of interleukin-17 in patients with alopecia areata and non-segmental vitiligo.
    Tomaszewska KA; Kozłowska M; Kaszuba A; Lesiak A; Narbutt J; Zalewska-Janowska AM
    Postepy Dermatol Alergol; 2022 Feb; 39(1):195-199. PubMed ID: 35369638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Study of Serum Level of Interleukin-2, Interleukin-6, and Tumor Necrosis Factor-alpha in Stable and Progressive Vitiligo Patients from Sina Hospital in Tabriz, Iran.
    Ranjkesh MR; Partovi MR; Pashazadeh M
    Indian J Dermatol; 2021; 66(4):366-370. PubMed ID: 34759394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased systemic and epidermal levels of IL-17A and IL-1β promotes progression of non-segmental vitiligo.
    Bhardwaj S; Rani S; Srivastava N; Kumar R; Parsad D
    Cytokine; 2017 Mar; 91():153-161. PubMed ID: 28082234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unraveling the relation between vitiligo, Interleukin 17, and serum amyloid A.
    Ahmed AAE; Mikhael NW; Elfallah AA; Hamed AM
    J Cosmet Dermatol; 2022 Nov; 21(11):6428-6433. PubMed ID: 36005895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokines: the yin and yang of vitiligo pathogenesis.
    Singh M; Kotnis A; Jadeja SD; Mondal A; Mansuri MS; Begum R
    Expert Rev Clin Immunol; 2019 Feb; 15(2):177-188. PubMed ID: 30462555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of helper and regulatory T cells in the pathogenesis of vitiligo.
    Basak PY; Adiloglu AK; Ceyhan AM; Tas T; Akkaya VB
    J Am Acad Dermatol; 2009 Feb; 60(2):256-60. PubMed ID: 19022528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-33 circulating serum levels are increased in patients with non-segmental generalized vitiligo.
    Vaccaro M; Cicero F; Mannucci C; Calapai G; Spatari G; Barbuzza O; Cannavò SP; Gangemi S
    Arch Dermatol Res; 2016 Sep; 308(7):527-30. PubMed ID: 27388717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin 38 serum level is increased in patients with vitiligo, correlated with disease severity, and associated with signs of disease activity.
    Mahmoud Marie RE; Adel AM; Abd El-Fadeal NM; Eyada MMK
    J Cosmet Dermatol; 2022 Aug; 21(8):3515-3521. PubMed ID: 34783147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.